Skip to main
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity is on track to achieve its guidance for Revtorpyk's commercial shipments to begin in late 3Q26, and the management believes September's announcement will be a real potential catalyst for the stock. Recent data from a physician survey supports a bullish outlook on the launch trajectory and peak sales potential for gedatolisib, and the company has a strong financial position with a cash runway into 2029. Additionally, the Phase 3 VIKTORIA-1 trial showed promising results for both PIK3CA wild-type and mutant tumors, and the company is making progress in its mCRPC program with potential updates in 4Q26. However, risks to the investment thesis include potential commercialization, regulatory, and intellectual property challenges.

Bears say

Celcuity is a clinical-stage biotechnology company that is facing potential challenges with its lead therapeutic candidate, gedatolisib, as the FDA has highlighted concerns about adverse events leading to discontinuations and dose modifications. The company is also facing competition in an increasingly competitive development landscape for treatments in HR+/HER2- metastatic breast cancer. Despite plans for an sNDA submission for the PIK3CA mutant patient population in 3Q26, it is uncertain whether Celcuity will be able to successfully navigate these challenges and achieve commercial success for gedatolisib.

Celcuity (CELC) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Celcuity (CELC) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $153.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $153.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.